Investigating the structure-activity relationships of N `-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against Trypanosoma cruzi to design novel active compounds

Autor(es):Mostrar menos -

Palace-Berl, Fanny ^[1] ; Mesquita Pasqualoto, Kerly Fernanda ^[2] ; Zingales, Bianca ^[3] ; Moraes, Carolina Borsoi ^[4] ; Bury, Mariana ^[3] ; Franco, Caio Haddad ^[4] ; da Silva Neto, Adelson Lopes ^[1] ; Murayama, Joao Sussumu ^[1] ; Nunes, Solange Lessa ^[3] ; Silva, Marcelo Nunes ^[3] ; Tavares, Leoberto Costa ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Fac Pharmaceut Sci, Dept Biochem & Pharmaceut Technol, Sao Paulo, SP - Brazil

^[2] Butantan Inst, Innovat & Ind Dev Lab, Sao Paulo, SP - Brazil

^[3] Univ Sao Paulo, Chem Inst, Dept Biochem, Sao Paulo, SP - Brazil

^[4] CNPEM, Lab Nacl Biociencias LNBio, Campinas, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY; v. 144, p. 29-40, JAN 20 2018.
• Citações Web of Science: 3

Resumo

Chagas disease, caused by the protozoan Trypanosoma cruzi, is a neglected chronic tropical infection endemic in Latin America. New and effective treatments are urgently needed because the two available drugs - benznidazole (BZD) and nifurtimox (NFX) - have limited curative power in the chronic phase of the disease. We have previously reported the design and synthesis of N'-{[}(5-nitrofuran-2-yl) methylene] substituted hydrazides that showed high trypanocidal activity against axenic epimastigote forms of three T cruzi strains. Here we show that these compounds are also active against a BZD- and NFX-resistant strain. Herein, multivariate approaches (hierarchical cluster analysis and principal component analysis) were applied to a set of thirty-six formerly characterized compounds. Based on the findings from exploratory data analysis, novel compounds were designed and synthesized. These compounds showed two-to three-fold higher trypanocidal activity against epimastigote forms than the previous set and were 25-30-fold more active than BZD. Their activity was also evaluated against intracellular amastigotes by high content screening (HCS). The most active compounds (BSF-38 to BSF-40) showed a selective index (SI') greater than 200, in contrast to the SI' values of reference drugs (NFX, 16.45; BZD, > 3), and a 70-fold greater activity than BZD. These findings indicate that nitrofuran compounds designed based on the activity against epimastigote forms show promising trypanocidal activity against intracellular amastigotes, which correspond to the predominant parasite stage in the chronic phase of Chagas disease. (C) 2017 Elsevier Masson SAS. All rights reserved. (AU)

• Processo FAPESP: 13/13333-8 - Quimioterapia para a Doença de Chagas: falhas terapêuticas para benznidazol e busca de candidatos para alternativas de tratamento
• Beneficiário: Bianca Silvana Zingales
• Linha de fomento: Auxílio à Pesquisa - Regular
• Processo FAPESP: 14/06061-4 - Nitrocompostos com atividade em Trypanosoma cruzi: planejamento, síntese, avaliação da citotoxicidade e bioatividade in vitro e estudos de relações estrutura-atividade in silico
• Beneficiário: Leoberto Costa Tavares
• Linha de fomento: Auxílio à Pesquisa - Regular